Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating,

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Eli Lilly stock recovered Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO) now offers a more compelling setup than GLP-1 category leader Eli Lilly (NYSE:LLY) after a peak-to-current decline of roughly 68% from Novo’s mid-2024 high near $127 to recent levels near $40.

Eli Grant has a history on Days of Our Lives that goes beyond when the character first appeared as an adult in February 2017. So we’re here to fill in the blanks and answer any questions you might have about his past in Salem. Lamon Archey has been ...

Surging consumer demand for blockbuster weight-loss drugs helped offset declining prices for those drugs.

Eli Lilly is a leader in one of today’s biggest growth markets: weight loss drugs. The company recently won approval for an exciting new product. They are part of the GLP-1 class of drugs that have taken the world by storm -- demand for these products has been so high at times that it's even created supply shortages.